CTLA4 and melanoma: This is of particular interest, since anti-CTLA4/ipilimumab was shown to engage non-classical monocytes ex vivo, resulting in antibody-dependent cell-mediated cytotoxicity (ADCC) of Tregs in melanoma patients [35].